Pfizer (PFE) Ibrance Positive in Phase III Breast Cancer Study

Pfizer Inc PFE announced that detailed results of phase III PALOMA 2 study evaluating the combination of its breast cancer drug Ibrance palbociclib and Novartis AG s NVS Femara letrozole for the treatment of first line ER HER2 metastatic breast cancer were published in The New